drug
luspatercept
Marketedupdated 5mo agoby Celgene Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(6)
approval · 6
Nov 8, 2019
approval
REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval
luspatercept
→
Apr 3, 2020
approval
REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval
luspatercept
→
Jul 8, 2022
approval
REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval
luspatercept
→
Aug 28, 2023
approval
REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval
luspatercept
→
May 16, 2024
approval
REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval
luspatercept
→
Feb 27, 2026
approval
REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval
luspatercept
→
Trials studying luspatercept
- —A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept
- phase2A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
- —First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms
- phase2Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
- —A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
- —Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China
- phase2Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- phase3ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
News(5)
- An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.biopharma_dive · 2mo ago
- Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsSanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.biopharma_dive · 2mo ago
- BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delaysStrong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…biospace · 2mo ago
- Dr Hunter on Luspatercept and Other Treatment Options for Anemia in MyelofibrosisAnthony M. Hunter, MD, discusses treatment decision-making for the management of anemia in myelofibrosis.onclive · 4mo ago
- Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookInvestors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.biopharma_dive · 5mo ago
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that